FOR IMMEDIATE RELEASE

September 27, 2004.

Girindus has received the prestigious Frost & Sullivan "Product Differentiation Award" for outstanding advances in the industrial production of therapeutic oligonucleotides.

Girindus AG - listed in the Prime Segment of the German Stock Exchange -focused on process development and manufacturing of drug actives for the worldwide pharmaceutical and biotechnology industry, is the 2004 recipient of the Frost & Sullivan "Product Differentiation Award" for its innovative developments in the commercial production of oligonucleotides.

The consulting firm Frost & Sullivan selected Girindus after conducting an extensive industry-wide survey of oligonucleotide manufacturers. The award citation stated that Girindus, a worldwide market leader in the manufacture of therapeutic oligonucleotides, holds a leading position on the basis of both its conventional solid-phase production methods and its recently-developed one-of-a-kind solution-phase process.

"The recognition of our accomplishments in the manufacture of therapeutic oligonucleotides makes us very proud," commented Fritz Link, CEO of Girindus AG. He added: "For the first time, our innovative solution-phase process has gained full market recognition in addition to our solid-phase production."

In the recently published analysis of its market research study, Frost & Sullivan attested that Girindus now has an enormous sales potential as a result of this product differentiation strategy.

Every year Frost & Sullivan confers its "Product Differentiation Award" on a company whose corporate strategy and innovation give it a decisive edge over its competitors and whose differentiation strategies have had an impact on the maturation of the individual markets.

CONTACTS: